The ACC Global Hub is the home for International cardiology professionals within the ACC, advocating for and advancing the priorities of the ACC members worldwide.

People who use e-cigarettes are significantly more likely to develop heart failure compared with those who have never used them, according to one of the largest prospective studies to date ...

About 50% of U.S. adults will develop high BP during their lifetime. High BP is the most prevalent and modifiable risk factor for cardiovascular disease and all-cause mortality. The overarching BP ...

The One Big Beautiful Bill Act (OBBBA) became law on July 4, cutting more than $1 trillion in Medicaid funding and making substantial changes to the federal student loan program. When the U.S. House ...

The Centers for Medicare and Medicaid Services (CMS) released the 2026 Hospital Outpatient Prospective Payment System (OPPS) and Ambulatory Surgical Center (ASC) Payment System proposed rule on July ...

The U.S. Department of Health and Human Services (HHS) and U.S. Department of Agriculture have released new Dietary Guidelines for Americans intended to guide federal nutrition policy for the next ...

Until about 15 years ago, most cardiologists were found in private practices, where the physicians – usually in groups – owned the practice and had privileges for hospital-based services at one or ...

I am honored to serve as the new Chair of this dynamic community, and I am excited to work alongside all of you. As cardiovascular professionals dedicated to advancing our field, our collective ...

The U.S. Food and Drug Administration (FDA) has approved acoramidis as a treatment to help reduce cardiovascular death and cardiovascular-related hospitalization in patients with transthyretin amyloid ...

In recent years, numerous health care challenges have been tackled, some making headlines, while others quietly escalate under the radar – like polypharmacy. Cardiovascular medications frequently lead ...

The U.S. Food and Drug Administration (FDA) has approved the Sapien 3, Sapien 3 Ultra and Sapien 3 Ultra Resilia TAVR valves from Edwards Lifesciences to treat patients with asymptomatic severe aortic ...

As the new year begins, the landscape of cardiovascular medicine is undergoing a remarkable transformation, driven by groundbreaking technologies and innovative approaches that promise to ...